All In Biotech

Drug Trial Radar · NCT05196035

A Study to Learn More About How Well the Study Treatment Finerenone Works, How Safe it is, How it Moves Into, Through, and Out of the Body, and the Effects it Has on the Body When Taken With an ACE Inhibitor or Angiotensin Receptor Blocker in Children With Chronic Kidney Disease and Proteinuria

A 6-month Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety and PK/PD of an age-and Body Weight-adjusted Oral Finerenone Regimen, in Addition to an ACEI or ARB, for the Treatment of Children, 6 Months to <18 Years of Age, With Chronic Kidney Disease and Proteinuria

Last checked: Nov 20, 2026Latest source record: Oct 15, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 219 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

219

Planned (sponsor's estimate)

Start

Mar 28, 2022

Primary completion

Apr 10, 2027

Study completion May 10, 2027

Sponsor

Lead sponsor
BayerBayer (BAYRY)
Sponsor type
Industry
First posted
Jan 19, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 months, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for a better way to treat children who have chronic kidney disease (CKD), which is long-term kidney disease, and proteinuria, a condition in which a person´s kidneys leak protein into the urine. The kidneys filter waste and fluid from the blood to form urine. In children with CKD, the kidney´s filters do not work as well as they should. This can lead to accumulation of waste and fluid in the body and proteinuria. CKD can lead to other medical problems, such as high blood pressure, also known as hypertension. Vice versa, hypertension and proteinuria can also contribute to worsening of CKD. Therefore, the treatment of CKD aims to control blood pressure and proteinuria. There are treatments available for doctors to prescribe to children with CKD and hypertension and/or proteinuria. These include "angiotensin-converting enzyme inhibitors" (ACEI) and "angiotensin receptor blockers" (ARB). Both ACEI and ARB can improve kidney function by helping the renin-angiotensin-aldosterone system (RAAS) to work normally. The RAAS is a system that works with the kidneys to control blood pressure and the balance of fluid and electrolytes in the blood. In people with CKD, the RAAS is often too active, which can stop the kidneys from working properly and cause hypertension and proteinuria. However, ACEI or ARB treatment alone does not work for all patients with CKD as they only target the angiotensin part of the renin-angiotensin-aldosterone system. The study treatment, finerenone, is expected to help control RAAS overactivation together with an ACEI or ARB. So, the researchers in this study want to learn more about whether finerenone given in addition to either an ACEI or ARB can help their kidney function. The main purpose of this study is to learn more about whether finerenone added to either ACEI or ARB can help reduce the amount of protein in the participants' urine more than a placebo. A placebo looks like a treatment but does not have any medicine in it. Participants will also continue to receive their other medications. To see how the treatment work, the doctors will take samples of the participants' urine to measure their protein levels before and during taking treatment and after their last treatment. In addition, blood samples will be taken to monitor kidney function, electrolytes and the amount of finerenone in the blood as well as for other tests. This study will include children with CKD and proteinuria aged from 6 months up to less than 18 years. The participants will take: * either finerenone or the placebo, in addition to * either ACEI or ARB, whichever they take as part of their normal treatment Two visits are required up to 104 days, to check whether a child can take part in the treatment phase of the study. If participants qualify for the treatment phase, they will then undergo treatment for about 180 days. During this time, they will visit the study site at least 7 times. During these visits, the participants will: * have their blood pressure, heart rate, temperature, height and weight measured * have blood and urine samples taken * have physical examinations * have their heart examined by an electrocardiogram and echocardiography (a sonogram of the heart) * answer questions about their medication and whether they have any adverse events , or have their parents or guardians answer * answer questions about how they are feeling, or have their parents or guardians answer * answer question about how they like the study medication, or have their parents or guardians answer The doctors will keep track of any adverse events. An adverse event is any medical problem that a participant has during a study. Doctors keep track of all adverse events that happen in studies, even if they do not think the adverse events might be related to the study treatments. The doctors will check the participants' health about 30 days after the participants take their last treatment.

Conditions

  • Chronic Kidney Disease
  • Proteinuria

Interventions

  • Finerenone (Kerendia, BAY94-8862)Drug

    Finerenone in different doses, treatment duration will be 180±7 days

  • PlaceboDrug

    Placebo to finerenone, treatment duration will be 180±7 days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in Urinary protein-to-creatinine ratio (UPCR) reduction from baseline to day 180+/-7Time frame: From baseline to day 180+/-7

Locations

132 sites in 32 countries. Site status is shown where the registry gives one.

  • Lucille Packard Children's Hospital Stanford - Pediatric Nephrology

    Palo Alto, California

  • UC San Diego - Altman Clinical and Translational Research Institute (ACTRI) - Linda Vista Clinic

    San Diego, California

  • Memorial Transplant Institute - Pediatric Nephrology

    Hollywood, Florida

  • The Charlotte R. Bloomberg Children's Center Building - Nephrology

    Baltimore, Maryland

  • Children's Mercy Hospital Kansas City - Nephrology

    Kansas City, Missouri

  • Cincinnati Children's Hospital Medical Center | Division of Nephrology and Hypertension

    Cincinnati, Ohio

  • Cleveland Clinic | Pediatric Nephrology

    Cleveland, Ohio

  • OHSU Doernbecher Children's Hospital - Neurology

    Portland, Oregon

  • Eccles Primary Children's Outpatient Services - Nephrology

    Salt Lake City, Utah

  • Seattle Children's Hospital - Nephrology

    Seattle, Washington

  • Instituto Universitario Hospital Italiano de Buenos Aires | Hospital Italiano de Buenos Aires - Neurology Department

    Buenos Aires, Argentina

  • Hospital General de Ninos Pedro de Elizalde | Nephrology Department

    Buenos Aires, Argentina

  • Hospital General de Ninos Ricardo Gutierrez | Pediatric Nephrology Department

    Buenos Aires, Argentina

  • Centro de Rehabilitacion Cardiovascular | San Luis, Argentina

    San Luis, Argentina

  • Clinica de Nefrologia, Urologia y Enfermedades Cardiovascualares | Santa Fe, Argentina

    Santa Fe, Santa Fe Province, Argentina

  • Queensland Children's Hospital

    South Brisbane, Queensland, Australia

  • Monash Children's Hospital

    Clayton, Victoria, Australia

  • Royal Children's Hospital Melbourne

    Parkville, Victoria, Australia

  • Uniklinikum Salzburg - Landeskrankenhaus

    Vienna, State of Vienna, Austria

  • Medizinische Univ Graz | Kinder & Jugendheilkunde

    Graz, Styria, Austria

  • Kepler Universitätsklinikum Campus IV

    Innsbruck, Tyrol, Austria

  • AKH Wien | Kinder & Jugendheilkunde, Kindernephrologie

    Vienna, Vorarlberg, Austria

  • CHC Montlégia - Pediatrics

    Liège, Belgium

  • Huderf / Ukzkf

    Brussels, Brussels Capital, Belgium

  • CU Saint-Luc/UZ St-Luc

    Brussels, Brussels Capital, Belgium

  • UZ Gent

    Ghent, East Flanders, Belgium

  • UZ Gasthuisberg - Pediatric Nephrology

    Leuven, Flemish Brabant, Belgium

  • Instituto da Crianca e do Adolescente

    São Paulo, Brazil

  • Hospital PUC-Campinas | Centro de Pesquisa Clínica Sao Lucas

    São Paulo, Brazil

  • Santa Casa de Misericórdia de Belo Horizonte

    São Paulo, Brazil

  • Hospital Pequeno Principe

    Curitiba, Paraná, Brazil

  • Hosp Clínicas Facult. Med. de Ribeirão Preto / USP

    Ribeirão Preto, São Paulo, Brazil

  • UMHAT Sveti Georgi

    Plovdiv, Plovdiv Province, Bulgaria

  • Alberta Children's Hospital | Nephrology Clinic

    Calgary, Alberta, Canada

  • Centre hospitalier universitaire Sainte-Justine | Cardiology

    Montreal, Quebec, Canada

  • Všeobecná fakultní nemocnice v Praze

    Prague, Prague, Czechia

  • Fakultní nemocnice Motol a Homolka, Pracoviště MOTOL

    Prague, Prague, Czechia

  • Rigshospitalet - Børn og Unge

    Copenhagen, Capital Region / Region Hovedstaden, Denmark

  • Aarhus Universitetshospital - Børn og Unge

    Aarhus N, Central Denmark Region / Region Midtjylland, Denmark

  • Odense Universitetshospital - HC Andersen Børne og Ungehospital

    Odense, Region of Southern Denmark / Region Syddanmark, Denmark

Showing 40 of 132 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.